G1 THERAPEUTICS INC (GTHX)

US3621LQ1099 - Common Stock

4.47  +0.18 (+4.2%)

After market: 4.49 +0.02 (+0.45%)

News Image
a month ago - G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

News Image
a month ago - G1 Therapeutics

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights ...

News Image
a month ago - G1 Therapeutics

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference...

News Image
a month ago - G1 Therapeutics

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024...

News Image
a month ago - Seeking Alpha

G1 Therapeutics stock sinks 53% in wake of study update (NASDAQ:GTHX)

G1 Therapeutics (GTHX) stock sank 53% Tuesday, the day after the company issued an update for a Phase 3 study of its breast cancer drug trilaciclib. Read more here.

News Image
a month ago - InvestorPlace

Evercore ISI Is Warming Up to NextEra Energy (NEE) Stock

NextEra Energy stock is on the move Tuesday after Evercore ISI initiated coverage of NEE shares with a bull rating and price target.

News Image
a month ago - InvestorPlace

UBS Just Upped Its Nvidia (NVDA) Stock Price Target

Nvidia stock is a hot topic among NVDA traders on Tuesday after the company's shares got a new $850 price target from UBS analysts.

News Image
a month ago - InvestorPlace

Why Is Polished.com (POL) Stock Down 33% Today?

Polished.com stock is sliding lower on Tuesday as investors in POL react to the company missing a debt payment and other dangers.

News Image
a month ago - InvestorPlace

Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?

G1 Therapeutics stock is down on Tuesday after the company provided GTHX investors with an update on a Phase 3 clinical trial.

News Image
a month ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are a hot topic on Tuesday and we're diving into all of the biggest winners and losers this morning!

News Image
a month ago - Seeking Alpha

G1 Therapeutics stock dives 36% post-market on P3 study update (NASDAQ:GTHX)

Shares of G1 Therapeutics (GTHX) plunged 36% in post-market trading after the company said the independent data monitoring committee overseeing a pivotal Phase

News Image
a month ago - G1 Therapeutics

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC...

News Image
3 months ago - G1 Therapeutics

G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference

G1 Therapeutics provides Corporate and Clinical Update at the 42md Annual J.P. Morgan healthcare conference. ...

News Image
3 months ago - G1 Therapeutics

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference...

News Image
3 months ago - G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 2024 Inducement Grants...

News Image
4 months ago - G1 Therapeutics

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent...

News Image
4 months ago - G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., Dec. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today...